Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14274449 | 0.89 | CA12 (0.39) | CA12CA1CA9PREPDRD2 | |
| SCHEMBL6027683 | 0.89 | CA12 (0.39) | CA12CA1CA9PREPDRD2 | |
| SCHEMBL17974012 | 0.86 | CA12 (0.36) | CA12CA1CA9PREPIDO1 | |
| SCHEMBL1417464 | 0.85 | CA12 (0.35) | CA12CA1CA9PREPIDO1 | |
| SCHEMBL23723314 | 0.83 | CA12 (0.42) | CA12CA1CA9PREP | |
| SCHEMBL1416957 | 0.83 | CA12 (0.42) | CA12CA1CA9PREPIDO1 | |
| SCHEMBL5855438 | 0.80 | PTGS2 (0.44) | CA1CA9 | |
| SCHEMBL16410318 | 0.78 | IDO1 (0.39) | IDO1 | |
| SCHEMBL4406786 | 0.77 | CA12 (0.38) | CA12CA1CA9PREP | |
| SCHEMBL378877 | 0.76 | CA12 (0.42) | CA12CA1CA9PREPIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725436-B2 | Cytochrome P450 inhibitors and their method of use | CORTENDO AB (PUBL) (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725436-B2 | Cytochrome P450 inhibitors and their method of use | CORTENDO AB (PUBL) (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160221990-A1 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | HAYFIN SERVICES LLP (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160221990-A1 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | HAYFIN SERVICES LLP (GB) | 2016-08-04 | — | — | US | disclosed |
| EP-3044210-A2 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | Cortendo AB (publ) (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | CA12 1714/4885CA1 1776/4885CA9 828/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | CA12 1714/4885CA1 1776/4885CA9 828/4885 |
| US-20160221990-A1 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | CYP11B1, CYP11B2, CYP21A2 | CA12 2578/4885CA1 2260/4885CA9 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.